-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
Clinical trial end points relevant to patients and society for rare cancers
Shelize Khakoo, Alexandros Georgiou & Ian Chau
Clinical Trail Methodology: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
The importance of monitoring adverse events in statin, and other, clinical trials
Beatrice Alexandra Golomb
Editorial: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
Autoregressive integrated moving average in clinical trials
Ton Cleophas
Commentary: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
The European Network of Gynecological Oncology Trial groups
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, Del Campo J,Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A
Research Update: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation